Addus HomeCare (ADUS)
(Delayed Data from NSDQ)
$94.76 USD
-1.16 (-1.21%)
Updated Apr 23, 2024 04:00 PM ET
After-Market: $94.74 -0.02 (-0.02%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth B Momentum A VGM
Addus HomeCare (ADUS) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$109.13 | $130.00 | $88.00 | 16.73% |
Price Target
Based on short-term price targets offered by eight analysts, the average price target for Addus HomeCare comes to $109.13. The forecasts range from a low of $88.00 to a high of $130.00. The average price target represents an increase of 16.73% from the last closing price of $93.49.
Analyst Price Targets (8 )
Broker Rating
Addus HomeCare currently has an average brokerage recommendation (ABR) of 1.44 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by nine brokerage firms. The current ABR compares to an ABR of 1.44 a month ago based on nine recommendations.
Of the nine recommendations deriving the current ABR, six are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 66.67% and 22.22% of all recommendations. A month ago, Strong Buy made up 66.67%, while Buy represented 22.22%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 6 | 6 | 6 | 6 | 6 |
Buy | 2 | 2 | 2 | 2 | 2 |
Hold | 1 | 1 | 1 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.44 | 1.44 | 1.44 | 1.25 | 1.25 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
2/27/2024 | Raymond James | John W Ransom | Moderate Buy | Moderate Buy |
2/5/2024 | William Blair | Jared Haase | Not Available | Strong Buy |
11/2/2023 | Stephens | Scott Fidel | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.44 |
ABR (Last week) | 1.44 |
# of Recs in ABR | 9 |
Average Target Price | $109.13 |
LT Growth Rate | 11.60% |
Industry | Medical - Outpatient and Home Healthcare |
Industry Rank by ABR | 156 of 252 |
Current Quarter EPS Est: | 1.10 |